Related Experiment Videos
Bexarotene is a new treatment option for lymphomatoid papulosis
Richard A Krathen1, Staci Ward, Madeleine Duvic
1Division of Internal Medicine, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Tex 77030-3597, USA.
Background:
Lymphomatoid papulosis (LyP) is a clonal T cell proliferation with large cell histology, a chronic course, and an increased risk of lymphoma. Bexarotene (Targretin) is an RXR-selective retinoid (rexinoid) approved for the cutaneous manifestations of cutaneous T cell lymphoma.
Objective:
To determine whether bexarotene is effective in treating LyP.
Methods:
Ten patients with chronic and symptomatic LyP were prospectively treated with oral (n = 3) or topical gel (n = 7) formulations of bexarotene.
Results:
A favorable response to bexarotene treatment with decreased numbers or duration of lesions was seen in all with objective responses in 8 patients.
Conclusions:
Bexarotene may be an effective palliative treatment for LyP, warranting further controlled studies.